EAM Investors’s Acceleron Pharma XLRN Stock Holding History

EAM Investors’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-18,014	Closed	-$1.72M	–	384
2020 Q2	$1.72M	Sell	18,014 -5,745	-24%	-$554K	0.38%	123
2020 Q1	$2.13M	Buy	+23,759	New	+$1.85M	0.66%	48
2019 Q1	–	Sell	-31,625	Closed	-$1.38M	–	348
2018 Q4	$1.38M	Sell	31,625 -21,892	-41%	-$1.09M	0.37%	125
2018 Q3	$3.06M	Buy	+53,517	New	+$2.63M	0.46%	109
2017 Q4	–	Sell	-56,427	Closed	-$2.11M	–	375
2017 Q3	$2.11M	Buy	+56,427	New	+$1.96M	0.28%	182
2014 Q1	–	Sell	-37,871	Closed	-$1.5M	–	370
2013 Q4	$1.5M	Buy	+37,871	New	+$914K	0.27%	143

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM Investors's XLRN Position: Q3 2020 in Review

EAM Investors sold out of Acceleron Pharma (XLRN) in Q3 2020, closing a stake of 18,014 shares — an estimated $1.72M sold.

EAM Investors first reported a position in XLRN in Q4 2013 and held it in 6 quarters. The position peaked at $3.06M in Q3 2018. 238 funds tracked by Wall St. Rank hold XLRN as of Q3 2020.

EAM Investors reported no remaining Acceleron Pharma position as of Q3 2020 after selling out during the quarter.
EAM Investors sold 18,014 Acceleron Pharma shares in Q3 2020, an estimated $1.72M.
EAM Investors first reported a position in Acceleron Pharma in Q4 2013 and held it in 6 quarters.
EAM Investors's Acceleron Pharma position peaked at $3.06M in Q3 2018.
238 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2020.

Based on EAM Investors's 13F filing for Q3 2020, filed 13 Nov 2020.